Repeated 4-aminopyridine seizures reduce parvalbumin content in the medial mammillary nucleus of the rat brain by Vizi, Sándor et al.
www.elsevier.com/locate/molbrainresMolecular Brain ResearchResearch report
Repeated 4-aminopyridine seizures reduce parvalbumin content in the
medial mammillary nucleus of the rat brain
Sa´ndor Vizia, Andrea Bagosib, Bea´ta Krisztin-Pe´vab, Ka´roly Gulyaa, Andra´s Miha´lyb,*
aDepartment of Zoology and Cell Biology, University of Szeged, Szeged, Hungary
bDepartment of Anatomy, Histology and Embryology, University of Szeged, P.O.B. 427, H-6701 Szeged, Hungary
Accepted 31 August 2004
Available online 3 October 2004Abstract
Parvalbumin (Pv) containing fast spiking neurons play a crucial role in synchronizing the activity of excitatory neuronal circuits in the
brain. Alterations of parvalbumin content in these neurons can affect their spike characteristics and, ultimately, may increase the susceptibility
of neuronal circuits to epileptic seizures. In the present study, we examined whether repeated 4-aminopyridine (4-AP)-induced seizures
modify the regional parvalbumin contents in the rat brain. 4-Aminopyridine was injected intraperitoneally in adult rats, controls received the
solvent. Animals were sacrificed at 3 h after a single acute treatment, or following repeated, daily treatments of 12 days. In situ hybridization
(ISH) indicated significantly decreased parvalbumin mRNA level in the medial mammillary nucleus (MM) at 12 days. Western blotting
revealed 20.1% significant decrease of parvalbumin content in the medial mammillary area, while parvalbumin immunohistochemistry
indicated no change of the number of immunoreactive cells in the medial mammillary nucleus. The results reveal the downregulation of the
transcription of the parvalbumin gene and the decrease of parvalbumin synthesis in medial mammillary nucleus neurons in response to
experimental seizures.
D 2004 Elsevier B.V. All rights reserved.
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Epilepsy comprises heterogeneous chronic disorders of
the nervous system characterized by spontaneous recurrent
seizures [51]. Seizure activity itself is due to abnormally
synchronized rhythmic activity of large assemblies of
neurons [32]. The complex pathological mechanisms
responsible for evoking epileptiform neuronal discharges
are intensively investigated at the molecular, cellular and
system levels of the nervous system.
Current molecular epilepsy research employing both
forward and reverse genetics approaches has revealed more0169-328X/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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epileptic syndromes [39]. Intriguingly, the affected genes
code not only for molecules playing a direct role in shaping
neuronal activity, but also for other proteins involved in
such diverse cellular processes as intracellular signalling,
regulation of gene expression, cell division, cell migration
and cell death. The ongoing functional characterization of
these genes may reveal crucial steps in seizure generation at
the molecular level. Even then, full appreciation of the
interacting processes leading to epileptic seizure generation
can only be achieved by incorporating results from cellular
and system studies into experimental epilepsy models.
To date, various cellular processes have been implicated
in seizure generation and, accordingly, different hypotheses
have been proposed [12,52–54]. Several epilepsy models
assign a crucial role for specific interneuron classes in131 (2004) 110–118
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activity of cortical excitatory neurons and, thus, generation
of rhythmic discharges in cortical networks is largely
dependent on these cells. In turn, seizure-inducing alter-
ations in the physiological activity of interneurons have also
been attributed to changes in the activity pattern of their
afferent excitatory input [8].
Parvalbumin (Pv), a highly diffusible cytosolic Ca2+-
binding protein [24], is a cellular marker for fast spiking
interneurons in various regions of the rat brain [25–27]. The
discharge characteristics of these interneurons are supposed
to be critically dependent on the Ca2+-buffering action of Pv
[22,24,29,30,33,47]. In the present study, we applied the
convulsant agent 4-aminopyridine (4-AP) [44] to induce
generalized seizures. Then, we examined whether the
experimentally induced single and repeated seizures modi-
fied the Pv content in various regions of the rat brain. Post-
seizure modification of the Pv content in fast-spiking
neurons could be both indicative of, and a reason for the
alterations in their physiological function.2. Materials and methods
2.1. Experimental animals and treatments
Male Sprague–Dawley rats (120–140 g) were housed in
groups under standard conditions (temperature 23 8C, lights
on from 06:00 to 18:00 h) and with free access to water and
food. The animals were injected intraperitoneally with
0.067% (w/v) solution of the convulsant 4-AP (Sigma; St.
Louis, MO, USA) dissolved in physiological saline (0.9%
NaCl in distilled water). The applied dose was 5 mg/kg
body weight, as this concentration proved to be convulsive
in previous studies [34,35]. Control animals received
appropriate volumes of physiological saline. In acute
experiments, 4-AP treated and control rats received a single
injection, and after 3 h were sacrificed under deep diethyl-
ether anesthesia. In chronic experiments, animals were
injected either with 4-AP or with saline daily for 12 days,
and sacrificed 3 h after the last injection, as described above.
The animals were observed for 2 h after every injection, and
their convulsive behaviour was rated according to Racine
[45]. Animals were killed in groups of five for Pv in situ
hybridization (ISH), and in groups of four for Western
blotting and in groups of three for Pv immunohistochem-
istry (IHC).
For ISH, brains were quickly removed, embedded in
Cryomatrix (Shandon Scientific; Pittsburgh, PA), immedi-
ately frozen at 70 8C, and stored at 20 8C until further
processing. Frozen brains both from the acute and chronic
experiments were sectioned on a cryostat in the coronal
plane at the thickness of 15 Am. Sections cut at bregma
3.14 and 4.52 [41] were thaw-mounted onto 3-amino-
propyl-triethoxysilane (Sigma) coated slides, air-dried, and
stored at 20 8C until further processing.For IHC, animals were deeply anesthetized with diethyl-
ether and perfused transcardially with 200 ml of 0.1 M
phosphate buffered saline (PBS, pH 7.4), followed by 300
ml of 4% phosphate buffered paraformaldehyde (pH 7.4).
The brains were removed and postfixed in 4% phosphate
buffered paraformaldehyde (pH 7.4) for 1 h. After post-
fixation, the brains were cryoprotected overnight in 30%
sucrose in 0.1 M phosphate buffer (pH 7.4). Coronal frozen
sections were cut on a freezing microtome at the thickness
of 24 Am at bregma 4.52 and processed for IHC.
All procedures of the animal experiments were licensed by
the Committee for Animals in Experimental Research, Uni-
versity of Szeged, according to the directive of the European
Council (86/609/EEC) and to the Hungarian Animal Act.
2.2. cRNA probes
The only Pv gene in the rat [6] contains five exons and
codes for two mRNA species by means of alternative
polyadenylation [17]. A template for a gene-specific cRNA
probe was created by isolating the 133 bp long third exon of
the rat Pv gene [3] by genomic polymerase chain reaction
(PCR) using the primers 5V-CCCCCCAACAGCTGCA-
GACTCC-3V and 5V-TTTACCCCAGCTCATCCTCCT-
CAATG-3V. The PCR product was inserted into the
pcDNA3 vector (Invitrogene, Carlsbad, CA) between
BamHI and EcoRI restriction sites and cloned using standard
methods [46]. Identity of the insert was confirmed by
sequencing (AB 373 DNA Sequencer; PE Applied Bio-
systems, Foster City, CA). For the production of antisense
and sense Pv cRNA probes, the vector construct was
linearized either with BamHI or EcoRI (Promega, Madison,
WI, USA), respectively. Then, the linearized plasmid was
transcribed in vitro by using Riboprobe System-T7 and
Riboprobe System-SP6 (Promega) according to the manu-
facturer’s instructions. For radiolabelling, [35S]UTPa´S (ICN
Biomedicals; Costa Mesa, CA) was incorporated during the
syntheses of the cRNA probes. The antisense and sense Pv
[35S]cRNA probes were purified by size exclusion chroma-
tography using ProbeQuant G-50 Sephadex microcolumns
(Pharmacia Biotech; Uppsala, Sweden) and their specific
activities were determined to be 3.1107–6.4107 cpm/
pmol by liquid scintillation counting.
2.3. In situ hybridization
Our protocol for in situ hybridization has been previously
described in detail [56,57]. Briefly, coronal rat brain
sections were fixed for 5 min in 2 SSC containing 4%
formaldehyde at RT and washed twice in 2 SSC for 1 min
at RT. Then, the sections were rinsed in 0.1 M triethanol-
amine containing 0.25% acetic anhydride and 0.9% NaCl,
pH 8.0 for 5 min at RT, dehydrated, and air-dried. Next, the
sections were hybridized in 50 Al hybridization solution
(50% formamide, 6 SSPE, 5 Denhardt’s reagent, 10%
dextran sulfate, 50 mM DTT, 100 Ag/ml salmon sperm
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probe. The concentrations of the Pv antisense and sense
hybridization solutions ranged from 247 to 288 fmol/ml.
Hybridization was performed under Parafilm coverslips in a
humid chamber at 55 8C for 24F0.5 h. The sections were
rinsed once in 2 SSC/50% formamide at RT for 5 min,
twice in 2 SSC/50% formamide at 50 8C for 10 min, and
then in 2 SSC at RT for 5 min. The sections were next
incubated in 1 TE containing 0.5 M NaCl and 1.32103
Kunitz U (~25 mg protein)/ml RNase A at 37 8C for 30 min,
and rinsed in 2 SSC/50% formamide at 50 8C for 10 min
and in 2 SSC at 50 8C for 10 min. Sections were
dehydrated, air-dried and processed for phosphorimaging.
2.4. Western blotting
Rats in diethyl-ether anesthesia were decapitated 3 h after
the last 4-AP or saline injection. The heads were immersed
in liquid nitrogen, and the brains were dissected on ice. The
mammillary area was cut out, chilled in liquid nitrogen and
stored at 80 8C until use. The number of animals was 16: 8
treated with 4-AP for 12 days, and 8 controls (injected daily
with saline for 12 days). The tissues were homogenized in
50 mM Tris–HCl (pH 7.5) containing 2 mM phenyl-
methanesulfonyl fluoride (PMSF), 150 mM NaCl, 0.1%
Nonidet-P-40, 2 Ag/ml leupeptin, 1 Ag/ml pepstatin and 2
mM EDTA. Protein concentrations were determined accord-
ing to the method of Lowry et al. [31]. Thirty-five
micrograms protein was separated on a 10% SDS-poly-
acrylamide gel and transferred onto nitrocellulose mem-
brane (Schleicher and Schuell, Dassel, Germany).
Membranes were blocked for 1 h in 5% nonfat dry milk
in Tris–HCl (pH 7.5) containing 0.9% NaCl (TBS) and
0.05% Tween 20, and incubated overnight with mouse anti-
Pv antibody (Sigma PA-235; dilution 1:3000). After 55
min washes in TBS-Tween 20 on room temperature, the
membranes were incubated for 1 h with biotinylated goat
anti-mouse IgG (Vector Laboratories; Burlingame, CA,
USA; dilution 1:1000), and washed three times as before.
The enhanced chemiluminescence method (ECL Plus West-
ern blotting detection reagents; Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK) was then used to
reveal immunoreactive bands, according to the manufactur-
er’s protocol. The other chemicals were from Sigma. The
intensity of the bands was quantified by densitometry and
expressed as pixel volume (pixel intensityarea) using the
Gel-Doc system (Biorad). For quantitative comparisons,
each value was calculated based on at least seven
independent determinations. An analysis of variance
(ANOVA) followed by post hoc analysis (Tukey’s multiple
comparison) was used to evaluate the significance.
2.5. Immunohistochemistry
Coronal, frozen brain sections (24 Am thin) were reacted
with monoclonal mouse anti-Pv antibody (Sigma PA-235,dilution 1:15,000). For the detection of the primary antibody,
biotinylated goat anti-mouse IgG (Vector) and streptavidin-
HRP (Vector) were employed. The immunoperoxidase
reaction was developed by using 3V3V-diaminobenzidine
tetrahydrochloride (DAB; Sigma) as a chromogen. The
sections were mounted on microscope slides, dehydrated and
coverslipped with Entellan (Fluka). Details of the immuno-
histochemical procedure are found in Ref. [35].
2.6. Imaging and image analysis
Hybridized rat brain sections and membrane standard
scales [40], previously calibrated to brain paste standard
scales [57], were co-exposed to SR Cyclone storage
phosphor screens (Packard Instrument, Meriden, CT) for
24 h at RT. Linearity of the densitometric graph of the
detection system was confirmed previously [56]. Phos-
phorimages were captured with Cyclone Storage Phosphor
System (Packard) at 600600 dpi resolution and analysed
by the computer program OptiQuant version 4.0 (Packard).
Images of brain areas were outlined on the computer
screen and their signal intensities were expressed in digital
light units (dlu) per mm2. Labelling values of brain areas
were corrected for the screen background (less than 7000
dlu/mm2) and the resulting values were expressed in net
dlu/mm2.
Consecutive steps of conversion of net dlu/mm2 values to
net ISH copy no./mm2 values were described earlier in
detail [56]. Labelling values of brain areas (net dlu/mm2)
were converted to membrane labelling values (net dlu/mm2)
using a previous calibration [57]. Further conversion steps
can be summarized in the equation
RES ¼ LAB AVOð Þ= LRF  RDF  SPAð Þ
where RES is the result (ISH copy number/mm2), LAB is
the labelling intensity (net dlu/mm2), AVO is the Avogadro
number (6.022521023 copy number/mol), LRF is the
labelling vs. radioactivity factor [(net dlu/mm2)/(cpm/
mm2)], RDF is the radioactive decay factor, and SPA is
the specific activity of the cRNA probe (cpm/pmol).
Correction for the tissue background was performed by
taking into account the specific activities of the cRNA
probes. The screen background-corrected labelling value of
a brain region hybridized with the antisense Pv cRNA probe
was converted to a RES value and then corrected for the
average of the RES values of the co-exposed brain sections
hybridized with a similar concentration of the sense Pv
cRNA probe. The resulting net RES value (ISH copy
number/mm2) was regarded as an estimate of the regional
copy no/mm2 value of the Pv mRNA.
The immunoreactive cells in the mammillary complex
were counted using a Nikon Eclipse 600 microscope
equipped with a Spot RT Slider digital camera (1600
1200 dpi in 8 bits), and the Image Pro Plus 4.5 morphometry
software (Media Cybernetics, Silver Spring, MD, USA).
Fig. 1. Seizure symptoms according to Racine [45], observed in one of the
experimental animals during the 12 days of the 4-AP treatment. Stage 1:
mouth and facial movements; stage 2: head nodding; stage 3: forelimb
clonus; stage 4: rearing; stage 5: full motor seizure (rearing and falling with
loss of postural control). Similar observations were made in every 4-AP
treated animal.
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every animal. The areas of interest (AOI) for cell counts
were selected from the medial mammillary nucleus.
Following background subtraction, the threshold was
adjusted so that the counting program could equally
recognize pale- and deep-stained cells. Cell counts were
done using a 40 objective. The AOI was the rectangular
image-capturing field of the camera (222 Am296 Am). We
also measured the thickness of the section and the diameter
of the cells using differential interference contrast (DIC)Fig. 2. Expression of Pv mRNAs in the rat brain following acute (3 h: A–D) and ch
and at bregma 4.52 were hybridized with antisense (A–H) and sense (I) Pv
displaying significant changes in Pv mRNA contents in 4-AP treated animals whe
Bonferroni tests; see main text). Arrow on B points to the reticular thalamic nucleu
hippocampus; DG, granular cell layer of the hippocampus; Fr, frontal cortex; Mol
2L and 2M; RSG, retrosplenial granular cortex. Bar represents 5 mm.optics, with the M7rzhauser MultiControl 2000 motorized
stage. The thickness data were rectified for the refractive
index of the dry objective [21]. The neuron number was
obtained and corrected with the help of the following
formula:
Cell number ¼ Number of counted cells
 Section thickness
= Section thicknessþ Cell diameterð Þ
[1,14,20].
2.7. Data processing
Data reduction was accomplished with the computer
software Excel 2002 (Microsoft, Redmont, WA). For Pv
ISH data, one or two outlier data points were excluded
from the data sets when they compromised the normal
distribution of the experimental data (examined by
Shapiro-Wilk W and skewness tests, pb0.05). Analysis
of significance was carried out with independent samples
Student’s t-test ( pb0.01 or 0.001), ANOVA followed by
a post hoc Bonferroni test ( pb0.05), and Median test
( pb0.05). For Pv IHC data, two-tailed Student’s t-test
( pb0.05) was employed. Cell numbers of Pv immuno-
histochemistry measurements in the medial mammillary
nucleus were analysed with independent samples t-test.
A significance criterion of pb0.05 was used. The
statistical analysis was performed with the SPSS 9.0
software.ronic (12 days: E–H) 4-AP treatment. Coronal sections cut at bregma 3.14
[35S]cRNA probes. Arrowheads indicate the medial mammillary nucleus
n compared to the corresponding controls ( pb0.05; ANOVA and post hoc
s. Abbreviations: CA1 and CA3, CA1 and CA3 pyramidal cell layer of the
HC, molecular layer of the hippocampus; Oc2L and Oc2M, occipital cortex
Table 1
Regional abundances of Pv mRNAs in the rat brain after acute and chronic
4-AP treatmentsa
Area 3 h 12 days
Cerebral neocortex (layers 2–6)
Frontal 91.1F16.4 102.8F19.0
89.8F11.9 110.9F32.9
Hindlimb 124.8F18.4 125.5F17.8
120.7F13.7 140.0F32.9
Parietalb 155.3F14.8 181.3F27.9
166.2F21.5 194.3F38.1
Parietalc 117.1F16.8 147.8F21.2
120.9F14.4 143.7F16.4
Occipital 2M 101.3F19.1 108.6F16.0
86.7F4.9 117.1F17.7
Occipital 2L 136.4F20.1 134.5F23.3
129.4F20.1 147.4F32.8
Temporal 1 165.0F13.7 162.0F21.6
152.3F6.3 166.9F27.1
CA1 pyramidal cell layer,
hippocampus
142.4F28.9 142.6F32.4
122.7F38.8 163.1F39.9
CA3 pyramidal cell layer,
hippocampus
131.7F37.8 184.4F65.4
149.0F40.9 165.8F56.0
Granule cell layer,
dentate gyrus
120.7F22.0 119.6F16.3
100.3F17.4 135.8F39.7
Medial mammillary
nucleus
766.6F93.4 668.4F125.8
682.3F109.2 514.5F144.5 A
Lateral mammillary
nucleus
315.3F86.6 267.1F78.7
324.6F99.1 344.0F108.6
Reticular thalamic
nucleus
862.7F113.1 929.3F86.5
998.6F92.2 953.5F128.8
a Coronal cryostat sections cut at different levels of the rat brain were
hybridized with Pv [35S]cRNA probes and then exposed to a phosphor
screen. Digital images of brain sections were captured with a phosphor-
imager and labeling values for selected brain areas were measured in dlu/
mm2 units. Tissue background correction was performed by taking into
account the number of the labeled nucleotides in the antisense and sense Pv
[35S]cRNA probes and their radioactive decay. The presented values are
ISH copy numbers (103)FS.D. corresponding to 1 mm2 area of a 15-Am-
thick section. For each brain region, values for the control and 4-AP treated
groups are presented in the first and second row of data, accordingly.
Downward arrow symbolizes significantly decreased values for 4-AP
treated animals, respectively, as compared to the corresponding control
value ( pb0.05; ANOVA and post hoc Bonferroni tests; see main text).
b Bregma 3.14.
c Bregma 4.52 according to Ref. [41].
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3.1. Seizure behaviour following 4-AP treatment
The administration of 5 mg/kg 4-AP caused character-
istic seizure symptoms: mouth and facial movements (stage
1), head nodding and muscle tremor (stage 2), forelimb
clonus (stage 3), rearing (stage 4) and generalized tonic-
clonic seizure (GTCS, stage 5), with complete loss of
postural control [45]. The average latency of GTCS was
30.3 min (F1.4 min). These symptoms were detected
everyday, during the 12 days’ treatment, although the
severity and the stages showed slight variations (Fig. 1).
3.2. Quantification of regional Pv mRNA contents in the rat
brain following acute and chronic 4-AP treatment
Regional quantities of Pv mRNAs in the brains of rats
subjected to acute or chronic 4-AP treatment were
assessed by ISH employing Pv [35S]cRNA probes. Auto-
radiograms of sections hybridized with antisense Pv
[35S]cRNA probes displayed a characteristic labelling
pattern specific for Pv mRNAs (Fig. 2A–H), [50]. Images
of sections hybridized with sense Pv [35S]cRNAs had
very low level of labelling and did not exhibit brain
structure specific signals (Fig. 2I). Normal distribution of
experimental data was confirmed for each data set except
that of group 12 days 4-AP medial mammillary nucleus.
In this group, several data points with very similar values
compromised the normal distribution of data (skewness)
even when the number of measurements was doubled by
quantifying contralateral as well. The subnuclei [3] of the
medial mammillary nucleus (MM) could not be separated
on the ISH images (Fig. 2).
The Pv mRNA content of the forebrain regions of the 4-
AP treated rats were compared to that of the corresponding
control rats by using two-tailed Student’s t-test ( pb0.01).
None of the investigated neocortical and allocortical areas
displayed changes in Pv mRNA levels in our experiments
(Table 1). Daily convulsions induced by 4-AP through 12
days did not have any impact on the transcription of the Pv
gene in the cerebral cortex (Table 1). In the diencephalon,
Pv mRNA levels displayed a slight increase in group 3 h in
the thalamic reticular nucleus (nRt) (116%), while in group
12 days significant decreases (77%, n=20, pb0.001) were
observed in the MM of the hypothalamus. Data sets were
also compared with ANOVA followed by post hoc
Bonferroni test ( pb0.05, Table 1). When regional Pv
mRNA abundances in 4-AP groups were compared to those
in the corresponding controls groups, ANOVA and Bonfer-
roni tests indicated that changes of the nRt of the thalamus
are not significant (Table 1). Data sets of MM were further
analysed with the nonparametric Median test, which
reinforced that the decrease of Pv mRNA level in group
12 days 4-AP in the MM was highly significant, when
compared to 12 days control value, confirming the resultsfor this brain region obtained with the above parametric tests
(Table 1). The decreased level of Pv mRNA in the MM was
visible on the in situ hybridization images, too (Fig. 2).
Therefore, we further investigated the Pv content of the MM
with immunological methods.
3.3. Western blotting of the mammillary area
Pv immunoreactive bands were sharp (Fig. 3). The
samples from control and 4-AP-treated rats displayed a
visible density difference (Fig. 3). Densitometry of the
membranes revealed a 20.1F5.5% decrease of Pv signal
intensity in rat MM treated with 4-AP for 12 days,
compared to the controls (data from eight samples of
convulsing brains and seven samples from controls). The
Fig. 3. Western blots from 12 days control (C) and 12 days 4-AP-treated (4-
AP) animals. The ECL method displays visible differences between the two
bands. Density analysis of the blots revealed a 20.1% significant ( pb0.05)
difference, i.e. a 20.1% decrease of Pv content in the medial mammillary
area in convulsing animals.
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3.4. Quantitative analysis of Pv immunoreactive cells in the
medial mammillary nucleus of the rat brain after 4-AP
treatment
Pv immunohistochemistry was performed on brain
sections from rats subjected 12-day 4-AP treatment and
the control animals. The Pv immunoreactivity in the MMFig. 4. Pv immunopositive neurons in MM following 12 days saline (A) and 4
quantified and compared to corresponding control values (C). No changes were
animals. Scale bar 100 Am.(Fig. 4) was similar to that described [13]. Medium-sized
neurons with few dendritic processes contained Pv-like
staining. Regional densities of immunolabelled cell bodies
were determined for each experimental group. Values from
4-AP treated groups were compared to those from corre-
sponding control groups (independent samples Student’s t-
test, pb0.05). The number of PV-immunoreactive neurons
did not change in 4-AP-treated animals, compared to the
controls (Fig. 4), although the intensity of the staining did
show a visible decrease. No pathological cell forms were
detected in the 12 days 4-AP samples.4. Discussion
The analysis of the behavioural symptoms of daily 4-AP
treatment on the Racine’s scale [45] proved that generalized
seizures were precipitated every day during the treatment.
Literature data indicate that the observed behavioural
symptoms correspond to two to three short, tonic-clonic
EEG convulsions, which can be detected in the neocortex,
hippocampus, striatum and thalamus [18,36]. Although
these seizures are not returning spontaneously, they closely
resemble the EEG and cellular electrophysiological features-AP (B) treatment. The number of Pv immunopositive cells in MM were
detected. Note that the intensity of immunostaining is lower in convulsing
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model is suitable for the study of the role and alterations of
the limbic system during repetitive, short seizures.
The main finding of our experiments is that neocortical
and allocortical structures did not display changes in Pv
gene transcription during repetitive, short, chemically
induced convulsions. Our preliminary investigations indi-
cate that 12-day 4-AP treatment does not induce cell loss
and neuronal degeneration, or breakdown of the blood–
brain barrier. Literature data, concerning the changes of Pv
immunoreactive cells in experimental epilepsies relate the
changes to the seizure-induced cell loss and reorganization
of the local neuronal circuits [48,52]. Therefore, our results
do not contradict to existing literature evidence on Pv
expression in seizures.
However, the 4-AP evoked experimental seizures
induced significant changes in Pv mRNA levels in the
diencephalon. The nRt displayed the highest Pv mRNA
density and exhibited a modestly increased Pv mRNA level
3 h after the acute 4-AP treatment. However, these mRNA
changes were not significant. The nRt is known to play a
crucial role in controlling the activity of thalamocortical
circuits [55]. GABAergic neurons of the nRt receive
excitatory input via corticothalamic axon collaterals, while
they innervate and control the activity of thalamic relay
neurons projecting to neocortical areas [19]. Interestingly,
no elevation of Pv mRNA level in nRt was observed
following 12-day 4-AP treatment.
The other important finding of our experiments is that the
MM exhibited a highly significant loss of Pv mRNAs after
the chronic 4-AP treatment. As no decreased cell number
were observed in the mammillary nuclei in the 12 days
groups, the reduction in the Pv mRNA density is likely to
indicate the downregulation of the cellular mRNA content
in MM. To examine whether the lower Pv mRNA
abundance led to a decreased Pv protein content in MM
neurons, Western blotting experiments were also quantified
in this brain region. Western analysis indicated a signifi-
cantly decreased amount of Pv in MM, at 12 days.
Remarkably, the degrees of Pv mRNA loss and the decrease
in Pv protein content in group MM 12 days were very
similar (77% and 79.9%, respectively), suggesting a
coordinated downregulation of Pv at the transcriptional
and translational levels, respectively.
MM, a major element of the Papez-circuit, receives input
from the rostral subiculum and harbours neurons which fire
in phase with hippocampal (especially with CA1) theta
rhythm [7,28]. Due to these properties, MM is sensitive to
hippocampal seizures and likely to be involved in propagat-
ing epileptic activity through the mammillothalamic path-
way [38,38]. In fact, it has been shown experimentally that
mammillary nuclei and their closely associated structures
are selectively labelled with 14C-deoxyglucose in animals
pretreated with ethosuximide and challenged with the
convulsant agent pentylenetetrazol (PTZ) [37]. Further,
lesion of the mammillothalamic tract was highly protectiveagainst PTZ-induced seizures [38]. These data indicate that
hippocampal epileptic seizures can selectively activate
mammillary neurons. The convulsive agent 4-AP is a
blocker of voltage sensitive K+ channels [2], and is known
to induce Glu and GABA release in the hippocampus
accompanied by epileptiform EEG waves [18,35,42,43].
Therefore, the observed reduction of Pv content in MM
following 12 days of 4-AP induced experimental epilepsy
could well be due to the repetitive burst activity of the
hippocampal projections to the mammillary nuclei [4].
A similar phenomenon has been described in the hippo-
campus of epilepsy prone Mongolian gerbils, where Pv
immunoreactivity disappeared from the GABAergic cells
with the developmental onset of seizure activity, while the
number of the GABAergic neurons remained unchanged
[48,49]. When seizures were induced in rats by kainate
injection, loss of Pv immunoreactivity in the hippocampus
was accompanied by degeneration of GABAergic cells and
delayed neuronal death in CA1 and CA3 pyramidal cell
layers [9,10]. However, kainate is known to induce not only
seizure, but also excitotoxic cell death in the hippocampus
[10].
The role of Pv in neuroprotection is not clear: some
experimental data support the protective role, others do not
[16]. The significant downregulation of Pv in MM neurons
in our experiments is not supporting an exclusive neuro-
protective role, because no neuronal loss, or degeneration
were observed. More plausible explanation is that the
downregulation of Pv alters the electrical properties of the
MM neurons. According to literature data, Pv as a Ca2+
buffer modulates short-term synaptic plasticity, by enhanc-
ing depression and decreasing facilitation [11]. The results
obtained on Purkinje cells of Pv knockout mice indicated
that the absence of Pv might cause cumulative facilitation,
because Ca2+ fluxes are not regulated properly [11].
The MM contains projection neurons—the GABAergic
innervation of the rat MM originates from midbrain sources
and from the surrounding hypothalamic areas [3,4,23]. The
high Pv content of the MM neurons can be attributed to the
numerous Ca2+ conductances, which are operative in the
bursting activity of these cells [5]. Possibly, the Pv content
buffers the intracellular Ca2+, regulates facilitation and
depression [11] and protects against the damaging aftermath
of Ca2+ related intracellular cascades. The downregulation
of Pv genes and mRNA translation may indicate the
deleterious effects of repeated seizures: the MM neurons
may become more susceptible to Ca2+ effects, which later,
may lead to the damage and death of these cells. The 20.1%
decrease of Pv in MM is substantial, taking into account that
every Pv molecule has two Ca2+ binding sites [24]. It seems
that 12 days of regular, short seizures are not enough to
damage these cells, but we cannot rule out that repeated
convulsions longer than these presented in our experiments
may lead to the degeneration of the mammillary complex:
which is a common autopsy finding in long standing human
epilepsies [15].
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